ArticleHaematologica2026
Allo-defensive, multiplex base-edited, anti-CD38 CAR T cells for 'off-the-shelf' immunotherapy.
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiplex edited universal CAR T cells without the genomic cost.Haematologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chimeric antigen receptor (CAR) T-cell therapies are being widely investigated in both autologous and allogeneic settings, with gene editing providing new strategies to address barriers to mismatched cell therapies. Currently 'universal' donor-derived T-cell therapies require intensive lymphodepletion and are still prone to host-mediated rejection. CD38, a transmembrane glycoprotein involved in cell activation and bioenergetics, is a promising immunotherapy target for hematologic malignancies. Disruption of CD38 expression using base editing prevented fratricide between T cells expressing anti-CD38 CAR (CAR38). Additional base editing enabled generation of 'universal' donor CAR38-T cells, devoid of endogenous TCRαβ and human leukocyte antigen (HLA) molecules after disruption of T-Cell Receptor Beta Constant (TRBC), Beta-2 Microglobulin (B2M), and Regulatory Factor X5 (RFX5). Removal of cell surface HLA expression enabled evasion of anti-HLA antibodies in sera from sensitized donors and reduced allo-stimulation in mixed lymphocyte cultures, while TCRαβ disruption prevented allo-reactivity. In mixed lymphocyte cultures, CAR38 expression enabled potent 'allo-defense' activity against CD38+ allo-reactive cells. Multiplex base-edited CAR38-T cells exhibited antigen-specific antileukemic activity against human B, T, and myeloid malignancies and inhibited disease progression in humanized murine xenograft models. CAR38-T cells offer a potent 'off-the-shelf' strategy against CD38+ hematologic malignancies and long-lived plasma cells which can be associated with auto-antibody production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.